Medical News

Luck in Unluckiness: Influence of Anticoagulant Therapy on Severity of Stroke in Atrial Fibrillation

25. 4. 2022 Source: Anticoagulant Treatment

A recent Swiss study evaluated the severity, complications, and outcomes of cerebrovascular accidents (CVAs) in patients with atrial fibrillation considering prior anticoagulant therapy use and its type. This allowed for a comparison between direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs).

Gliflozins Successfully Treat Type 2 Diabetes Mellitus and Heart Failure

The number of patients with type 2 diabetes mellitus (DM2) and heart failure is increasing worldwide, and the combination of both diseases significantly worsens the prognosis of patients. One of the…

25. 4. 2022 Source: Heart Failure

New Drug in the Biologic Therapy Arsenal for Plaque Psoriasis

Bimekizumab shows promising effects in clinical studies with psoriasis patients. Let's take a closer look at this recently approved drug in our brief summary.

25. 4. 2022 Source: Psoriasis

Ceftaroline vs. Vancomycin in the Treatment of Acute Pulmonary Exacerbation of Cystic Fibrosis

Up to 25% of patients with cystic fibrosis are colonized with methicillin-resistant Staphylococcus aureus (MRSA). The first-line drug for acute pulmonary exacerbation is vancomycin. The study…

22. 4. 2022 Source: Anti-Infectives

Safety of Long-Term Therapy with Bevacizumab in Oncological Patients

The angiogenesis inhibitor bevacizumab is typically administered long-term. Therefore, a study published in the journal The Oncologist deals specifically with its long-term safety and tolerability in…

21. 4. 2022 Source: Oncological Treatment

Effectiveness of Idarucizumab Reversal Effect

It is, of course, a great advantage if doctors have a specific substance available that counteracts the effect of oral anticoagulants in urgent need. Idarucizumab is a humanized monoclonal antibody…

21. 4. 2022 Source: Anticoagulant Treatment

Pain Management After Day Surgery

Effective pain control is a crucial part of recovery for patients after painful surgical procedures. In clinical practice, combined analgesia using paracetamol and nonsteroidal anti-inflammatory…

21. 4. 2022 Source: Analgesia

Venetoclax Treatment Strategies in Patients with CLL

One of the new targeted preparations in the treatment of chronic lymphocytic leukemia (CLL) is the Bcl-2 inhibitor venetoclax. Its significant advantage is the potential to achieve deep remission,…

20. 4. 2022 Source: Chronic Lymphocytic Leukemia

Efficacy of Lorlatinib in Patients with ROS1-Positive NSCLC in Clinical Practice

Interesting real-world data have been brought by a study on the efficacy of lorlatinib in patients with non-small cell lung cancer (NSCLC) with a mutation in the ROS1 gene.

20. 4. 2022 Source: Genetic Profile and Treatment of NSCLC

Probiotics as a Means to Reduce the Incidence of Streptococcus Mutans

Data from a prospective study examining the effects of probiotics on the oral microbiome show the ability of orally administered probiotics to reduce the incidence of Streptococcus mutans and also…

19. 4. 2022 Source: GI, colic and microbiome

Long-term Efficacy of Targeted Therapy for Axial Spondyloarthritis

How does etanercept fare in the long-term treatment of early axial spondyloarthritis (axSpA)? Data from over 10 years of follow-up in patients with both radiographic and non-radiographic forms of…

19. 4. 2022 Source: Arthritis

Comparison of Cardiovascular Effects of Sitagliptin and Empagliflozin

Cardiovascular (CV) diseases remain the leading cause of death among patients with type 2 diabetes (T2D). Reducing the incidence of macrovascular CV events in diabetics requires more than just…

19. 4. 2022 Source: Diabetes

Prim. MUDr. Gustáv Ondrejka: Biological treatment of asthma eliminates the need for systemic corticotherapy

Despite advances in the therapy of bronchial asthma, a portion of patients still do not achieve the desired control of the disease. The introduction of biological treatment marked a significant…

18. 4. 2022 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation

Prophylaxis with Rurioctocog Alfa Pegol in Severe Hemophilia A

Rurioctocog alfa pegol represents a modern modality for the treatment of hemophilia from the group of factors with an extended half-life. The authors of a systematic review and meta-analysis…

14. 4. 2022 Source: Hemophilia

Impact of Prophylaxis on Reducing the Risk of Neurological Problems Associated with Bleeding in Hemophilia A

Bleeding can also cause complications in the nervous system of hemophiliacs. The authors of the work presented below discuss the significance of prophylactic administration of factor VIII coagulation…

14. 4. 2022 Source: Hemophilia

1 … 52 53 54 55 56 … 111

Back Filter by speciality

Remove filters